Search Clinical Trials
 
By Condition
 
By Location (USA)
 
By Location (Other)
 
By Sponsor
 
Resources
 
Privacy Policy
 
About Us
Disclaimer
Erlotinib in Treating Patients with Advanced Non-Small Cell Lung Cancer Clinical Trials Data presented on Clinical Trials Search is not meant to be a substitute for qualified medical advice, visits or professional assistance with a genuine dr.. We are not doctors. Always consult your mD about Erlotinib in Treating Patients with Advanced Non-Small Cell Lung Cancer conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Erlotinib in Treating Patients with Advanced Non-Small Cell Lung Cancer Clinical research trials and Erlotinib in Treating Patients with Advanced Non-Small Cell Lung Cancer medical trials take place in many of places throughout the U.S.A.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually evaluate the effectiveness of new does drugs. The purpose of the studies / projects is to solve specific human healthcare questions. Clinical trials are a popular way for mDs, government agencies, and private sector companies to find cures for all varieties of conditions, like Erlotinib in Treating Patients with Advanced Non-Small Cell Lung Cancer. Erlotinib in Treating Patients with Advanced Non-Small Cell Lung Cancer Clinical Trials and other clinical trials allow for volunteers to have health treatment options before they are available to the masses. Many times the human subjects acquire professional assistance for free of charge, and sometimes they are compensated for their time. Occasionally there is a cost for a Erlotinib in Treating Patients with Advanced Non-Small Cell Lung Cancer clinical trial. Test subjects typically obtain the finest healthcare available for their Erlotinib in Treating Patients with Advanced Non-Small Cell Lung Cancer condition. Dangers are a reality, nevertheless, and might include additional or frequent doctor trips, medical dangers (possibly life-jeopardising), and/or the treatment being ineffectual. Trials are federally regulated with strict guidelines to protect clinical trials patients.

Home > "E" Clinical Trials Conditions > Erlotinib in Treating Patients with Advanced Non-Small Cell Lung Cancer

Erlotinib in Treating Patients with Advanced Non-Small Cell Lung Cancer



Erlotinib in Treating Patients with Advanced Non-Small Cell Lung Cancer

For Condition: Carcinoma, Non-Small-Cell Lung
Status: Recruiting
Sponsor(s): OSI Pharmaceuticals ,
Synopsis: The purpose of this study is to determine if erlotinib will improve disease at doses that produce its characteristic rash in patients with advanced Non-Small Cell Lung Cancer.
Details: Only patients with 0 to 1 performance status on the ECOG scale are eligible.
Eligibility:
Study Type:  Interventional, Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: Inclusion Criteria: - Confirmed diagnosis of Stage IIIB or IV non-small cell lung cancer (histological or cytological). - Received prior chemotherapy treatment for advanced, metastatic non-small cell lung cancer. - Measurable disease per RECIST criteria. - Adequate bone marrow, hepatic, and renal function. Exclusion Criteria: - Breast cancer or skin cancer at any time in the past or any other cancer in the past 5 years. - Brain metastases that are unstable, require steroids, are life-threatening, or required radiation in the last 28 days. - Known hypersensitivity to minocycline. - History of serious cardiac disease that is not controlled. - Serious eye conditions. - Prior treatment with inhibitors of EGFR of any kind.
Total Enrollment: 50

Location and Contact Information:

CTRC Institute for Drug Development *Recruiting*
San Antonio,  Texas,  78229
United States
Recruiting OSIP  Information 800-572-1932


Additional Information:
Study ID Numbers:  OSI-774-202;  Dose to Rash
Study Start Date: August 2003
Record last reviewed: November 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00072631

Other Carcinoma, Non-Small-Cell Lung Studies:
1. This study is to compare the efficacy of ZD6474 and ZD1839 in subjects with NSCLC.

2. Phase II Neoadjuvant Trial of a Continuous Infusion of Paclitaxel Plus Cisplatin Followed by Chest Radiotherapy for Patients with Stage III Non-Small Cell Lung Cancer

3. Study of DN101 and Taxotere in patients with advanced non-small cell lung cancer

4. Phase 2 Study of TLK286 Administered Weekly in Advanced Non-Small Cell Lung Cancer

5. Vaccine Treatment for Advanced Non-Small Cell Lung Cancer

Related Studies:

Other Carcinoma, Non-Small-Cell Lung Clinical Trials
Other Texas Clinical Trials
Other San Antonio Clinical Trials

Erlotinib in Treating Patients with Advanced Non-Small Cell Lung Cancer
Modify your Search

  Other Carcinoma, Non-Small-Cell Lung Clinical Trials
  Other Texas Clinical Trials
  Other San Antonio Clinical Trials


Warning: include(/var/www/cgi-bin/traxis/counter.php) [function.include]: failed to open stream: No such file or directory in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103

Warning: include() [function.include]: Failed opening '/var/www/cgi-bin/traxis/counter.php' for inclusion (include_path='.:/usr/local/lib/php') in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103